Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisatracurium + neostigmine
- Development stage
- Phase 4
- Lead developer
- Organon
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination of cisatracurium, a non-depolarizing neuromuscular blocking agent, and neostigmine, a cholinesterase inhibitor used to reverse the neuromuscular blockade induced by cisatracurium. This combination is commonly used in anesthesia practice, where cisatracurium facilitates tracheal intubation and provides skeletal muscle relaxation during surgery, while neostigmine is administered afterward to antagonize the neuromuscular blocking effects and restore normal muscle function.
02
Targets
AcetylcholinesteraseMuscle-type nicotinic acetylcholine receptor
Beyond the preview
Go deeper on cisatracurium + neostigmine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisatracurium + neostigmine.